Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Merck & Co (NYSE:MRK)., the second-largest U.S. drugmaker by revenue, is facing a jury trial over accusations that it ...

Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Personalis (PSNL – Research Report) today and set a price target of ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

Selbyville, Delaware , Jan. 27, 2025 (GLOBE NEWSWIRE) -- Polydimethylsiloxane market was valued at USD 1.8 billion in 2024 and is projected to be worth USD 3.1 billion by the end of 2034, as per a ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.